The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BCDA | -45.83% | -96.01% | -47.49% | -99% |
| S&P | +14.49% | +91.09% | +13.83% | +220% |
BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.11M | 0.9% |
| Gross Margin | -3433.33% | 0.0% |
| Market Cap | $13.69M | 25.3% |
| Market Cap / Employee | $0.68M | 0.0% |
| Employees | 20 | 0.0% |
| Net Income | -$1.48M | 14.6% |
| EBITDA | -$1.38M | 16.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.29M | 7.2% |
| Accounts Receivable | $0.01M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.21M | -68.7% |
| Short Term Debt | $0.43M | 15.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -137.58% | 16.6% |
| Return On Invested Capital | 184.35% | -14.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.67M | 36.0% |
| Operating Free Cash Flow | -$1.67M | 36.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.58 | 13.96 | -6.01 | -3.77 | -173.44% |
| Price to Sales | 13.03 | 124.25 | 172.93 | 3924.95 | 17857.23% |
| Price to Tangible Book Value | 3.58 | 13.96 | -6.01 | -3.77 | -173.44% |
| Enterprise Value to EBITDA | -2.23 | -3.29 | -6.00 | -6.97 | 117.19% |
| Return on Equity | -703.6% | -737.9% | -317.5% | - | |
| Total Debt | $0.95M | $0.85M | $0.75M | $0.64M | -38.95% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
